Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet

February 2, 2026 updated by: TCI Co., Ltd.
The objective of this study is to evaluate the effect of liquid vitamin C and glutathione supplements on human skin condition improvement and anti-oxidation.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is a single-center, placebo-controlled, double-blinded, parallel human trial designed to evaluate the skin beauty and anti-oxidant effect of liquid vitamin C and glutathione supplements.

Healthy adult participants aged 18-65 years will be enrolled. Participants will be informed to consume test samples daily for 12 consecutive weeks. Skin measurement and self-assessment questionnaires will be conducted at baseline (before intake), after 4, 8 weeks, and 12 weeks of consumption. Fasting blood samples will be collected at baseline and after 12 weeks of consumption.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Taiwan
      • Pingtung City, Taiwan, 928
        • Recruiting
        • Chia Nan University of Pharmacy & Science
        • Principal Investigator:
          • Chia-Hua Liang, Ph.D.
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy male or female adults, aged 18-65 years old;
  • Commitment not to use products having activity comparable with that of the product to be tested during the study period;
  • Free of any dermatological or systemic disorder that would interfere with results.

Exclusion Criteria:

  • Subject with obvious skin surface damage;
  • Subject who had oral or topical medication which may affect skin condition within 1 month;
  • Individuals with known allergies to cosmetics, medications, or foods (especially those allergic to legumes/soy);
  • Pregnant or breastfeeding individuals;
  • Received facial laser therapy, chemical peeling in the past 2 months.
  • Individuals unwilling to allow publication or public disclosure of photographs taken as part of the study results

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo sachet
Dietary supplement: Placebo sachet
consume 1 sachet of the test samples daily for 12 consecutive weeks
Experimental: Vitamin C and Glutathione Liquid Sachet
Dietary supplement: Vitamin C and Glutathione Liquid Sachet
consume 1 sachet of the test samples daily for 12 consecutive weeks
Other Names:
  • Lipo GLUTA-C

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change of skin tone
Time Frame: Change from Baseline skin tone at 12 weeks
Chroma Meter MM500 was utilized to measure face skin tone. Units: Individual Typology Angle (ITA°)
Change from Baseline skin tone at 12 weeks
The change of visible spots
Time Frame: Change from Baseline visible spots at 12 weeks
VISIA Complexion Analysis was utilized to measure visible spots on face. Units: the amount of detectable visible spots
Change from Baseline visible spots at 12 weeks
The change of UV spots
Time Frame: Change from Baseline UV spots at 12 weeks
VISIA Complexion Analysis was utilized to measure UV spots on face. Units: the amount of detectable UV spots
Change from Baseline UV spots at 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change of skin collagen density
Time Frame: Change from Baseline skin collagen density at 12 weeks
DermaLab® Series SkinLab Combo was utilized to measure skin collagen density. Units: arbitrary units
Change from Baseline skin collagen density at 12 weeks
The change of skin melanin index
Time Frame: Change from Baseline skin melanin index at 12 weeks
Mexameter® MX18 (CK, Germany) was utilized to measure face skin melanin level. Units: arbitrary units
Change from Baseline skin melanin index at 12 weeks
The change of skin elasticity
Time Frame: Change from Baseline skin elasticity at 12 weeks
Skin elasticity (Softplus, Italy) was utilized to measure face skin elasticity. Units: arbitrary units
Change from Baseline skin elasticity at 12 weeks
The change of brown spots
Time Frame: Change from Baseline brown spots at 12 weeks
VISIA Complexion Analysis was utilized to measure brown spots on face. Units: the amount of detectable brown spots
Change from Baseline brown spots at 12 weeks
The change of wrinkles around the eyes
Time Frame: Change from Baseline wrinkles around the eyes at 12 weeks
VISIA Complexion Analysis was utilized to measure wrinkles around the eyes. Units: the amount of detectable wrinkles
Change from Baseline wrinkles around the eyes at 12 weeks
The change of skin texture
Time Frame: Change from Baseline skin texture at 12 weeks
VISIA Complexion Analysis was utilized to measure skin texture. Units: arbitrary units
Change from Baseline skin texture at 12 weeks
The change of total antioxidation capacity (TAC)
Time Frame: Change from Baseline TAC at 12 weeks
A fasting blood sample will be collected for TAC testing.
Change from Baseline TAC at 12 weeks
The change of Superoxide Dismutase (SOD)
Time Frame: Change from Baseline SOD at 12 weeks
A fasting blood sample will be collected for SOD testing.
Change from Baseline SOD at 12 weeks
The change of Glutathione S-transferase-Red Blood Cells (GST-RBC)
Time Frame: Change from Baseline GST-RBC at 12 weeks
A fasting blood sample will be collected for GST-RBC testing.
Change from Baseline GST-RBC at 12 weeks
The change of Malondialdehyde (MDA)
Time Frame: Change from Baseline MDA at 12 weeks
A fasting blood sample will be collected for MDA testing.
Change from Baseline MDA at 12 weeks
The change of skin hydration
Time Frame: Change from Baseline skin hydration at 12 weeks
Corneometer® CM825 (CK, Germany) was utilized to measure skin surface hydation. Units: arbitrary Corneometer® units 0-120.
Change from Baseline skin hydration at 12 weeks
The change of skin redness
Time Frame: Change from Baseline skin redness at 12 weeks
Chroma Meter MM500 was utilized to measure face skin redness. Units: a* value
Change from Baseline skin redness at 12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change of self-assessment fatigue level
Time Frame: Change from Baseline fatigue level at 12 weeks
Fatigue Symptom Inventory (FSI) was collected and evaluate fatigue level. Most items are rated on an 11-point Likert scale ranging from 0 to 10. The scores are generally averaged to create subscales for intensity and interference.
Change from Baseline fatigue level at 12 weeks
The change of blood liver function biomarkers (AST, ALT)
Time Frame: Change from Baseline liver function biomarkers at 12 weeks
A fasting blood sample will be collected for liver function biomarkers testing.
Change from Baseline liver function biomarkers at 12 weeks
The change of blood renal function biomarkers (creatinine, BUN)
Time Frame: Change from Baseline renal function biomarkers at 12 weeks
A fasting blood sample will be collected for renal function biomarkers testing.
Change from Baseline renal function biomarkers at 12 weeks
The change of self-assessment skin condition
Time Frame: Change from Baseline skin condition at 12 weeks
Skin condition was evaluated using a 5-point Likert scale (0-4) to assess the severity of skin-related symptoms. The scale was defined as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
Change from Baseline skin condition at 12 weeks
The change of self-assessment Low Immunity level
Time Frame: Change from Baseline Low Immunity level at 12 weeks
Low Immunity level was evaluated using a 5-point Likert scale (0-4) to assess the severity of Low Immunity-related symptoms. The scale was defined as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
Change from Baseline Low Immunity level at 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

TCI Co., Ltd.

Investigators

  • Principal Investigator: Chia-Hua Liang, Ph.D., Chia Nan University of Pharmacy & Science

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 24, 2026

Primary Completion (Estimated)

May 18, 2026

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

January 23, 2026

First Submitted That Met QC Criteria

January 23, 2026

First Posted (Actual)

January 30, 2026

Study Record Updates

Last Update Posted (Actual)

February 4, 2026

Last Update Submitted That Met QC Criteria

February 2, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 25-103-A

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Skin Condition

Clinical Trials on Placebo sachet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe